PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
482 views · Published 18 June 2015 · 5:23 · Indexed 23 September 2026
Channel: American Society of Hematology · 2015 · Nonprofits & Activism
Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
3:56
ASH and the Reagans Support Stem Cell Research
-
3:41
Advances in Hematology: Robert S. Negrin, MD
-
6:35
ASH News TV: Late Breaking Abstracts & ASH SAP 5th Addition
-
2:34
ASH State-of-the-Art Symposium
-
3:42
CLL-IPI: A New and Improved Staging System for CLL?
-
4:44
About the ASH Clinical Research Training Institute
-
1:52
2016 Highlights of ASH® na América Latina